Search research articles
Contact Us
Filters
Showing results (21-30 of 57) with videos related to
Page
of 6
Sort By:
The American Journal of Cardiology
|
February 24, 2022
Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus
Ariel Hammerman, Candace Makeda Moore, Enis Aboalhasan, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
June 16, 2017
The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel
Ariel Hammerman, Sari Greenberg-Dotan, Ilan Feldhamer, et al.
Diabetes/Metabolism Research and Reviews
|
May 30, 2020
Impact of flash glucose monitoring on glucose control and hospitalization in type 1 diabetes: A nationwide cohort study
Anat Tsur, Avivit Cahn, Meirav Israel, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
December 12, 2019
Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel
Noa Triki, Nachman Ash, Avi Porath, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 17, 2013
Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions
Dan Greenberg, Ariel Hammerman, Shlomo Vinker, et al.
Journal of Clinical Medicine
|
January 23, 2024
Can Consultation by a Clinical Pharmacist Prevent Morbidity and Mortality in Patients Undergoing Bariatric Surgery?
Carmil Azran, Almog Eliyahu Dahan, Orly Shimoni, et al.
Acta Oncologica (Stockholm, Sweden)
|
October 29, 2014
The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study
Ariel Hammerman, Sari Greenberg-Dotan, Erez Battat, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 24, 2010
Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization
Shmuel H Klang, Ariel Hammerman, Nicky Liebermann, et al.
Israel Journal of Health Policy Research
|
November 20, 2013
Oncologists' and family physicians' views on value for money of cancer and congestive heart failure care
Dan Greenberg, Ariel Hammerman, Shlomo Vinker, et al.
JCO Oncology Practice
|
November 15, 2023
Publicly Funded Cancer Care: Are Adjuvant Therapies Prioritized Over Treatment of Metastatic Cancer? The Israeli Experience
Ariel Hammerman, Carmil Azran, Yael Topol, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 57) with videos related to
Sort By:
Page
of 6
The American Journal of Cardiology
|
February 24, 2022
Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus
Ariel Hammerman, Candace Makeda Moore, Enis Aboalhasan, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
June 16, 2017
The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel
Ariel Hammerman, Sari Greenberg-Dotan, Ilan Feldhamer, et al.
Diabetes/Metabolism Research and Reviews
|
May 30, 2020
Impact of flash glucose monitoring on glucose control and hospitalization in type 1 diabetes: A nationwide cohort study
Anat Tsur, Avivit Cahn, Meirav Israel, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
December 12, 2019
Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel
Noa Triki, Nachman Ash, Avi Porath, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 17, 2013
Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions
Dan Greenberg, Ariel Hammerman, Shlomo Vinker, et al.
Journal of Clinical Medicine
|
January 23, 2024
Can Consultation by a Clinical Pharmacist Prevent Morbidity and Mortality in Patients Undergoing Bariatric Surgery?
Carmil Azran, Almog Eliyahu Dahan, Orly Shimoni, et al.
Acta Oncologica (Stockholm, Sweden)
|
October 29, 2014
The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study
Ariel Hammerman, Sari Greenberg-Dotan, Erez Battat, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 24, 2010
Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization
Shmuel H Klang, Ariel Hammerman, Nicky Liebermann, et al.
Israel Journal of Health Policy Research
|
November 20, 2013
Oncologists' and family physicians' views on value for money of cancer and congestive heart failure care
Dan Greenberg, Ariel Hammerman, Shlomo Vinker, et al.
JCO Oncology Practice
|
November 15, 2023
Publicly Funded Cancer Care: Are Adjuvant Therapies Prioritized Over Treatment of Metastatic Cancer? The Israeli Experience
Ariel Hammerman, Carmil Azran, Yael Topol, et al.
Page
of 6